Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies

Artios Pharma completed an oversubscribed $115 million Series D funding round in November 2025, co-led by SV Health Investors and RA Capital Management, with participation from Janus Henderson Investors and existing shareholders123.

The new capital will mainly support advancing two lead candidates:
the ATR inhibitor alnodesertib (in Phase 2 cohorts for pancreatic and colorectal cancer in ATM-negative patients) and the Polθ inhibitor ART6043 (heading into a randomized Phase 2 study in breast cancer)123.

The proceeds will also further develop a novel DDR inhibitor-antibody drug conjugate (DDRi-ADC) platform, with a lead candidate expected to be selected in early 20262.

Early clinical data for alnodesertib and ART6043 show promising results in difficult-to-treat solid tumors, and the company aims to broaden development into indications where current therapies have limited and short-lived benefits12.

The financing supports not only late-stage clinical development but also preparations for future commercialization as Artios transitions toward becoming a commercially oriented company13.

Sources:

1. https://www.startupresearcher.com/news/artios-raises-usd115-million-to-advance-ddr-cancer-therapies

2. https://www.biospace.com/press-releases/artios-announces-oversubscribed-115-million-series-d-financing-to-accelerate-clinical-programs-in-indications-of-high-unmet-need

3. https://www.artios.com/press-release/artios-announces-oversubscribed-115-million-series-d-financing-to-accelerate-clinical-programs-in-indications-of-high-unmet-need/